Bio-Rad Laboratories, Inc.
- Stock
- Ticker BIO
- ISIN US0905722072
- NYSE
Performance, volatility and drawdowns of Bio-Rad Laboratories, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $20,766. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −73.8% in 06/2025, measured from the peak in 09/2021. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 668 | 585 | 652 | 653 | 693 | 592 | 651 | 656 |
| Gross profit | 342 | 306 | 345 | 343 | 345 | 309 | 346 | 329 |
| Operating income | 58 | 24 | 77 | 65 | -119 | 34 | 73 | -50 |
| Net income | -716 | 64 | 318 | -342 | 720 | -527 | 371 | 459 |
| Earnings per share | -25.57 | 2.29 | 11.67 | -12.70 | 26.39 | -19.55 | 13.85 | 17.02 |
| Balance sheet | ||||||||
| Total assets | 9,364 | 9,527 | 10,214 | 9,696 | 10,577 | 9,790 | 10,252 | 10,783 |
| Liabilities | 2,795 | 2,848 | 3,085 | 2,960 | 3,123 | 2,939 | 3,078 | 3,180 |
| Equity | 6,569 | 6,679 | 7,129 | 6,737 | 7,454 | 6,851 | 7,174 | 7,603 |
| Cash | 488 | 521 | 369 | 396 | 530 | 507 | 517 | 465 |
| Long-term debt | 1,200 | 1,201 | 1,201 | 1,201 | 1,202 | 803 | 803 | 803 |
| Cash flow | ||||||||
| Operating cash flow | 124 | 130 | 117 | 121 | 165 | 108 | 99 | 96 |
| Capital expenditure | -43 | -34 | -46 | -32 | -46 | -30 | -32 | -31 |
| Free cash flow | 81 | 96 | 71 | 89 | 119 | 78 | 67 | 65 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2019 at +59.3%, weakest 2022 at −44.3%. 5 of 9 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 4 Nov 2026 | $17.02 |
| 4 Aug 2026 | $13.85 |
| 30 Apr 2026 | −$19.55 |
| 13 Feb 2026 | $26.39 |
| 29 Oct 2025 | −$12.70 |
| 31 Jul 2025 | $11.67 |
| 1 May 2025 | $2.29 |
| 14 Feb 2025 | −$25.57 |
| 31 Oct 2024 | $23.34 |
| 2 Aug 2024 | −$76.26 |
| 8 May 2024 | $13.45 |
| 16 Feb 2024 | $12.14 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €8.8bn
- Market cap in trading currency
- $9.67bn
- Enterprise value
- $9.21bn
- P/E
- 9.5
- P/S
- 3.73
- P/B
- 1.27
- EV/Sales
- 3.55
- EV/EBITDA
- –
- Earnings yield
- 10.5%
- FCF yield
- 3.4%
Results (last four quarters)
- Revenue
- $2.59bn
- Gross profit
- $1.33bn
- EBITDA
- –
- Net income
- $1.02bn
- Earnings per share
- $37.71
- Revenue per share
- $96.22
- Revenue growth
- +0.5%
- Earnings growth
- –
Profitability
- Gross margin
- 51.3%
- Operating margin
- -2.4%
- Net margin
- 39.5%
- Return on equity
- 14.3%
- Return on assets
- 9.5%
Balance sheet and cash flow
- Cash
- $1.66bn
- Cash per share
- $61.77
- Financial debt
- $1.20bn
- Debt/equity %
- 16
- Current ratio
- 3.18
- Book value per share
- $282.17
- Operating cash flow
- $468m
- Free cash flow
- $329m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- 0%
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 26.9m
- Volume
- 182,295
- Avg. volume 3 months
- 257,158
- Relative volume
- 0.7
Price and technicals
- Price
- $358.90
- 1 day
- −2.3%
- 52-week high
- $390.34
- 52-week low
- $241.71
- Distance to 52-week high
- −8.1%
- Distance to 52-week low
- +48.5%
- Distance to 50-day line
- −3.4%
- Distance to 200-day line
- +12.7%
- RSI (14)
- 43
- Volatility 1M
- 34.0%
Performance
- 1 week
- −2.0%
- 1 month
- −1.3%
- 3 months
- −6.0%
- 6 months
- +24.7%
- YTD
- +18.5%
- 1 year
- +17.8%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has BIO performed since 11/2016?
$10,000 grew to $20,766 by 20 Nov 2026, which is +7.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is BIO?
Volatility was 33.5% per year, measured on monthly returns. The largest decline from a peak was −73.8%, with the low in 06/2025.
How does BIO compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, BIO returned +7.6% at 33.5%. The correlation of monthly returns was 0.43; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.